QUESTIONS
Ipamorelin FAQ
Direct answers to the most-asked questions — body composition, appetite, safety, and the CJC-1295 combination — each cited to the literature.
Does ipamorelin reduce belly fat?
No human study has tested ipamorelin for belly fat. The closest data is a 2024 ferret study where intraperitoneal ipamorelin (1–3 mg/kg) reduced chemotherapy-induced body-weight loss by about 24% — that is protection against weight loss, not fat reduction [5]. In mice, ipamorelin actually raised fat-pad weight and leptin [6]. The fat-loss reputation rests on growth-hormone mechanism, not on measured human belly-fat outcomes.
What are the downsides of ipamorelin?
The biggest documented downside is that it may not work: the only published Phase 2 RCT (114 adults, 0.03 mg/kg IV twice daily up to 7 days) missed its primary endpoint, 25.3 h vs 32.6 h placebo (p=0.15) [3]. There is also a class-level cardiac signal from a related ghrelin-receptor agonist in rats [10], and no long-term human safety data. Commonly reported minor effects include facial flushing and increased hunger (anecdotal).
Does ipamorelin make you hungry?
It can, by mechanism. Ipamorelin activates the ghrelin ("hunger hormone") receptor, and central administration of ghrelin and GH secretagogues induces feeding in rats [7]. Community reports describe an appetite uptick in the hours after injecting, generally milder than with the older peptide GHRP-6 (anecdotal, not clinical evidence). In diabetic mice, ipamorelin also drove strong GH hypersecretion, underscoring that its signaling is potent [9].
Does ipamorelin increase appetite?
Yes, plausibly, through its ghrelin-receptor action. Ghrelin is the body's appetite-stimulating hormone, and GH secretagogues activate hypothalamic feeding circuits in animal studies [7]. Ipamorelin specifically raised fat mass and leptin in mice [6], consistent with an appetite-and-adiposity effect. The appetite increase is a class trait of ghrelin agonists; users report it as real but usually milder than older GHRPs (anecdotal).
Does ipamorelin cause water retention?
Mild water retention is occasionally reported by users (anecdotal), and it is mechanistically plausible because growth hormone excess is associated with sodium and water retention. There is no controlled human study quantifying it for ipamorelin. The one human trial, in a short perioperative window, recorded adverse events in 87.5% of the ipamorelin arm versus 94.8% of placebo, with no ipamorelin-specific safety signal [3].
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin / GH-secretagogue receptor (GHS-R1a) to release a pulse of growth hormone. Its defining trait is selectivity: it raises GH potently without meaningfully raising cortisol or prolactin, even at more than 200-fold its GH ED50 [1]. It was discovered at Novo Nordisk in the 1990s and is not an approved drug.
What does ipamorelin do for you?
In studies, ipamorelin triggers a clean growth-hormone pulse [1] and, in animals, affects bone growth [4], weight in wasting states [5], and adiposity [6]. In people, no controlled trial has demonstrated a body-composition or performance benefit, and its one human efficacy trial missed its endpoint [3]. Users anecdotally report better sleep and recovery (not clinical evidence). It does nothing that is proven in humans beyond raising GH acutely.
What is ipamorelin peptide?
Ipamorelin peptide is a wholly synthetic five-amino-acid chain (C38H49N9O5, ~712 Da, CAS 170851-70-4), developed under the code NNC 26-0161 [1]. It is not made by the human body; it mimics ghrelin at the GHS-R1a receptor. Non-natural building blocks make it resistant to enzymatic breakdown, and in its founding characterization it released GH selectively, without the cortisol spillover of older GH-releasing peptides [1].
What are the risks of ipamorelin?
The main risks are unknown long-term safety and unproven efficacy. The only human trial missed its endpoint and ran just up to 7 days [3]; no Phase 3 trial exists. A related ghrelin-receptor agonist caused dose-dependent myocardial degeneration in rats over 28 days [10], a class-level cardiac signal. GH-axis stimulation raises theoretical IGF-1/cancer and glucose-control concerns [1]. Research-grade material from unregulated suppliers also carries purity and sterility risks.
Why is ipamorelin being discontinued?
Ipamorelin was never an approved drug to discontinue. Its clinical development effectively stopped after the only Phase 2 trial, for postoperative ileus, missed its primary endpoint (25.3 h vs 32.6 h, p=0.15) [3]. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list and reviewed it at an October 2024 advisory meeting, tightening compounding-pharmacy access — which is often what "being discontinued" refers to.
What does CJC-1295 and ipamorelin do?
Together they aim to raise growth hormone two ways: CJC-1295 (a long-acting GHRH analog) sustains GH and IGF-1 output [11], while ipamorelin (a ghrelin-receptor agonist) adds a clean GH pulse [1]. A 2026 review found the combination improved maximal tetanic tension in a mouse muscle-loss model but stressed the evidence is limited to animal studies [15]. The pair has no controlled human outcome trial for body composition or performance.
Does ipamorelin increase IGF-1?
Not always. Ipamorelin raises growth hormone, which normally drives liver IGF-1 — but in a 15-day rat study it increased bone growth with no change in total IGF-1 [4], and in diabetic mice it drove GH hypersecretion alongside suppressed IGF-1 [9]. Sustained IGF-1 elevation is more reliably tied to GHRH analogs like CJC-1295 [11]; off-label, combined GHS therapy raised IGF-1 in hypogonadal men [12]. Short ipamorelin courses often do not.
How does CJC-1295 ipamorelin work?
The two peptides hit different receptors that both feed growth-hormone release. CJC-1295 activates the GHRH receptor for a sustained signal, producing 2- to 10-fold GH increases for days and sustained IGF-1 in healthy adults [11]. Ipamorelin activates the ghrelin receptor (GHS-R1a) for a discrete GH pulse without cortisol spillover [1]. The idea is that a steady GHRH analog plus a pulsatile GHRP combines durable IGF-1 with a clean pulse — though the combination is untested in trials [15].
How much CJC-1295 ipamorelin should I take?
No clinically validated human dose exists, and none is given here. There is no controlled human trial of the combination, so any specific figure online is community convention, not evidence [15]. The published human ipamorelin doses were IV, in a PK study and a failed Phase 2 trial [2][3], and CJC-1295's kinetics were characterized separately [11]. Because ipamorelin has no approved indication, this digest describes only what was studied and recommends no dose.
Does CJC-1295 ipamorelin work?
For raising GH and IGF-1, each component has measurable pharmacology — CJC-1295 sustains GH/IGF-1 [11] and ipamorelin produces a clean GH pulse [1][2]. For human body-composition or performance outcomes, there is no controlled-trial evidence that the combination works; the strongest recent data is a mouse muscle-loss model showing improved tetanic tension, with reviewers stressing the lack of human trials [15]. The mechanism is real; proof of a meaningful human result is not yet there.
How to reconstitute CJC-1295 ipamorelin 5mg?
This digest does not provide a human-use preparation protocol. As general research-handling background: ipamorelin is supplied as a lyophilized (freeze-dried) powder and reconstituted with bacteriostatic water; as a peptide it degrades with heat and repeated freeze-thaw, so solution is typically refrigerated. These are stability observations from the supply literature, not directions for dosing or self-administration, and the combination has no approved preparation standard [3].
How long does ipamorelin stay in your system?
In healthy human volunteers, ipamorelin's terminal half-life is approximately 2 hours after IV dosing, with clearance 0.078 L/h/kg [2]. Practically, that means most of the compound clears within a single day. The growth-hormone pulse it triggers is even shorter-lived, peaking around 40 minutes and then subsiding [2]. As a GH secretagogue, ipamorelin and its class are detectable in urine by accredited anti-doping laboratories.
Will I gain weight on ipamorelin?
Possibly, depending on context. In mice, ipamorelin raised body weight by ~15% and increased fat mass and leptin, even without growth hormone [6], and it can increase appetite through its ghrelin-receptor action [7]. In a chemotherapy model it protected against weight loss [5]. There is no human body-composition trial, and the one human efficacy trial measured no benefit on its endpoint [3]. Direction of weight change appears to depend heavily on the situation.
What does ipamorelin peptide do?
Ipamorelin peptide selectively switches on the ghrelin receptor (GHS-R1a) on the pituitary, releasing a pulse of growth hormone without much cortisol or prolactin [1]. Downstream, that GH pulse can affect bone growth and adiposity in animals [4][6], though it does not always raise IGF-1 [4]. In humans, no controlled trial has shown a body-composition or performance benefit, and its only efficacy trial missed its endpoint [3].
How long does it take for ipamorelin to work?
Its pharmacological action is fast: after an IV dose in humans, the growth-hormone pulse peaks around 40 minutes, with a ~2-hour terminal half-life [2]. That is the only directly measured human timing. Any longer-term "results" (the reported sleep or body-composition changes) are anecdotal and described over weeks, not established by trials. There is no validated timeline for a human body-composition effect because no such trial has been done.
Where to inject CJC-1295 ipamorelin?
This digest does not give injection-site instructions for human use. In the published studies, ipamorelin was given intravenously in humans [2][3] and subcutaneously or intraperitoneally in animals [4][5]. The combination with CJC-1295 has no controlled human trial and no approved administration protocol [15], so any community guidance on injection technique is not clinically validated and falls outside what this research digest covers.
Does ipamorelin cause cancer?
No ipamorelin study has measured cancer outcomes, so there is no direct evidence either way. The theoretical concern is mechanistic: growth hormone drives IGF-1, a mitogen that promotes cell growth [1][4], so chronically raising GH could in principle feed proliferative activity in an existing tumor. This is a class-level, mechanism-based caution — not a finding from any ipamorelin trial. People with active or recent cancer have a specific reason for caution on this basis.